Madhya Pradesh Online Journal

Knee Osteoarthritis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Knee Osteoarthritis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 10
19:30 2023
Knee Osteoarthritis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Knee Osteoarthritis pipeline constitutes 40+ key companies continuously working towards developing 40+ Knee Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Knee Osteoarthritis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.

 

Some of the key takeaways from the Knee Osteoarthritis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years. 
  • Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, Moebius Medical, Bioventus LLC, Novartis, UnicoCell Biomed, Gwo Xi Stem Cell Applied Technology, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment 
  • Emerging Knee Osteoarthritis therapies such as – M6495, PPV 06, LG00034053, StroMel, MM-II, PTP-001, Canakinumab, Elixcyte, GXCPC1, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.   
  • In October 2022, Updates to a Phase II trial examining the efficacy and safety of EP-104IAR for the treatment of knee osteoarthritis (“OA”) were made public by Eupraxia Pharmaceuticals Inc.A clean safety profile and no drug-related Serious Adverse Events were detected in Eupraxia’s current Phase II research, which has successfully completed all DSMB reviews, according to the company’s announcement
  • In September 2022, A licence agreement between KiOmed Pharma and Hansoh Pharmaceutical Group Company Limited was made public in order to develop and market KiOmedinevsOne, a carboxymethyl chitosan injection that has been approved for use in Europe to treat knee osteoarthritis, in mainland China, Macau, and Taiwan (the territory).According to the terms of the contract, KiOmed will receive a down payment, be eligible for milestone payments of up to € 66 million in research, regulatory, and commercial activities, as well as tier-based royalties on future product sales
  • In September 2022, Pluri Inc. reported that PROTO (Advanced Personalised Therapies for Osteoarthritis), an international partnership lead by Charité, Berlin Institute of Health Centre for Regenerative Therapies, had received a €7.5 million non-dilutive grant from the European Union’s Horizon Europe programme. The PROTO initiative seeks to treat mild to moderate knee osteoarthritis (OA) using Pluri’s PLX-PAD cells in a Phase I/IIa research
  • In December 2022, For its knee OA treatment candidate, lorecivivint (“LOR”), Biosplice Therapeutics, Inc. recently released potential structure-modifying highlights from the ongoing long term extension study, OA-07. The study’s findings continue to suggest that frequent injections of lorecivivint may be effective in preventing structural progression and symptom relief
  • In September 2021, The licencing agreement between Biosplice Therapeutics and Haisco Pharmaceutical Group Co., Ltd. was recently signed, and it gives Haisco the exclusive right to produce and market lorecivivint (SM04690) in China for the treatment of knee osteoarthritis (“OA”) and other musculoskeletal diseases

 

Knee Osteoarthritis Overview

The most typical type of arthritis is osteoarthritis (OA). Some people refer to it as “wear and tear” arthritis or degenerative joint disease. It usually affects the hands, hips, and knees. A joint’s cartilage starts to degrade and the underlying bone starts to change as a result of OA. These modifications typically take time to manifest and worsen.

 

Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

 

Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:

  • M6495: Merck KGaA
  • PPV 06: Peptinov
  • LG00034053: LG Chem
  • StroMel: Akan Bioscience
  • TTAX03: BioTissue,Inc.
  • EP-104IAR: Eupraxia Pharmaceuticals Inc.
  • OLP 1002: OliPass Corporation
  • JTA-004: Bone Therapeutics
  • X 0002: Techfields Pharma
  • Lorecivivint: Biosplice Therapeutics

 

Route of Administration

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type 

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Knee Osteoarthritis Pipeline Therapeutics Assessment

  • Knee Osteoarthritis Assessment by Product Type
  • Knee Osteoarthritis By Stage and Product Type
  • Knee Osteoarthritis Assessment by Route of Administration
  • Knee Osteoarthritis By Stage and Route of Administration
  • Knee Osteoarthritis Assessment by Molecule Type
  • Knee Osteoarthritis by Stage and Molecule Type

 

DelveInsight’s Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies

 

Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:

Key companies developing therapies for Knee Osteoarthritis are – Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, and others.

 

Knee Osteoarthritis Pipeline Analysis:

The Knee Osteoarthritis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
  • Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies

 

Knee Osteoarthritis Pipeline Market Drivers

  • Increase in prevalence of Osteoarthritis, robust Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.

 

Knee Osteoarthritis Pipeline Market Barriers

  • However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.

 

Scope of Knee Osteoarthritis Pipeline Drug Insight    

  • Coverage: Global
  • Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, Moebius Medical, Bioventus LLC, Novartis, UnicoCell Biomed, Gwo Xi Stem Cell Applied Technology, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others
  • Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, MM-II, PTP-001, Canakinumab, Elixcyte, GXCPC1, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others
  • Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
  • Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers 

 

Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials

 

Table of Contents

1

Knee Osteoarthritis Report Introduction

2

Knee Osteoarthritis Executive Summary

3

Knee Osteoarthritis Overview

4

Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment

5

Knee Osteoarthritis Pipeline Therapeutics

6

Knee Osteoarthritis Late Stage Products (Phase II/III)

7

Knee Osteoarthritis Mid Stage Products (Phase II)

8

Knee Osteoarthritis Early Stage Products (Phase I)

9

Knee Osteoarthritis Preclinical Stage Products

10

Knee Osteoarthritis Therapeutics Assessment

11

Knee Osteoarthritis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Knee Osteoarthritis Key Companies

14

Knee Osteoarthritis Key Products

15

Knee Osteoarthritis Unmet Needs

16 

Knee Osteoarthritis Market Drivers and Barriers

17

Knee Osteoarthritis Future Perspectives and Conclusion

18

Knee Osteoarthritis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services